Overview
Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor 1 (IGF-1) that is produced locally in muscle tissue in response to mechanical stress, such as resistance exercise or tissue damage. Also known as IGF-1Ec in humans (IGF-1Eb in rodents), MGF differs from the systemic IGF-1Ea isoform by a unique C-terminal E-domain peptide sequence that confers distinct biological activities.
The discovery of MGF's role in muscle repair was pioneered by Geoffrey Goldspink at University College London, who identified that mechanical loading of skeletal muscle induces alternative splicing of the IGF-1 gene, producing MGF as an early response factor. Unlike systemic IGF-1 which promotes muscle hypertrophy through differentiation, MGF primarily activates quiescent satellite cells (muscle stem cells) and promotes their proliferation before differentiation occurs.
This temporal distinction is critical: MGF expression is transient (peaking within hours of muscle damage and declining within 24–72 hours), while IGF-1Ea expression increases later and is sustained for days. The sequential expression of MGF followed by IGF-1Ea mirrors the physiological repair sequence—first expanding the satellite cell pool (MGF), then driving their differentiation and fusion into mature muscle fibers (IGF-1Ea).
Synthetic MGF peptides corresponding to the unique C-terminal E-domain (typically the 24-amino acid MGF C-terminal peptide) have been studied for muscle repair, cardiac regeneration, and neuroprotection, though no formulation has entered clinical trials.
Quick facts
- Mechanism
- IGF-1 splice variant activating muscle satellite cells after mechanical stress
- Primary use
- Muscle Repair & Satellite Cell Activation
- Evidence
- moderate
- FDA
- Not approved
- Route
- Intramuscular or subcutaneous injection
- Typical results
- Animal studies show enhanced muscle repair and satellite cell activation within 1–4 weeks
Chemical information
MGF (C₁₂₁H₂₀₀N₄₂O₃₉) is a anabolic compound with a molecular weight of ~2,867 g/mol. Its structural characteristics underpin its biological activity in anabolic processes and muscle development.
How MGF works
MGF activates muscle satellite cells through its unique C-terminal E-domain, which interacts with cell surface receptors distinct from the classical IGF-1 receptor (IGF-1R). This triggers satellite cell activation from quiescence (G0) into the cell cycle, promoting proliferation while delaying premature differentiation. The result is an expanded pool of myogenic precursor cells available for muscle repair and adaptation.
The unique 24-amino acid C-terminal E-domain of MGF contains a sequence that is not present in the mature IGF-1 protein or other IGF-1 splice variants. This domain has been shown to activate satellite cells independently of IGF-1R, likely through interaction with an as-yet-unidentified receptor. Studies have demonstrated that the MGF E-peptide alone (without the IGF-1 core) can stimulate satellite cell proliferation, confirming its autonomous bioactivity.
In the early phase of muscle repair, MGF upregulates MyoD and Myf5 transcription factors while suppressing myogenin, maintaining satellite cells in a proliferative state. As MGF levels decline and IGF-1Ea levels rise, the balance shifts toward myogenin expression and terminal differentiation, enabling myoblast fusion into multinucleated myofibers. This temporal coordination ensures adequate stem cell expansion before commitment to repair.
Beyond skeletal muscle, MGF has shown cardioprotective effects. In ischemia-reperfusion models, MGF administration reduced infarct size by 30–40% and improved cardiac function, likely through activation of cardiac progenitor cells and anti-apoptotic signaling. In neural tissue, MGF promotes neuronal survival through Akt phosphorylation and BAD inactivation.
- Satellite cell activation: Unique E-domain triggers quiescent stem cells into proliferative state
- Proliferation vs differentiation: Upregulates MyoD/Myf5 while suppressing premature myogenin expression
- IGF-1R independent: C-terminal E-peptide acts through a distinct, unidentified receptor
- Temporal expression: Early transient response (hours) preceding sustained IGF-1Ea expression
- Multi-tissue protection: Cardioprotective and neuroprotective effects beyond skeletal muscle
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Weight | ~2,867 g/mol | 24-amino acid E-domain peptide |
| Half-life | ~5–7 minutes | Extremely short; PEGylation extends to hours (PEG-MGF) |
| Site of Action | Local (paracrine/autocrine) | Naturally acts locally in damaged tissue, not systemically |
| Expression Timing | Peaks 1–2 hours post-damage | First responder in the IGF-1 repair cascade |
Dosing & administration
MGF dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for MGF is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Potent activation of muscle satellite cells for enhanced repair
- • Complementary to IGF-1 by expanding stem cell pool before differentiation
- • Cardioprotective effects in ischemia-reperfusion models
- • Neuroprotective through anti-apoptotic signaling
- • Mimics the natural post-exercise repair cascade
- • May enhance exercise adaptation and recovery
Serious / potential risks
- • Very short half-life (~5–7 minutes) limiting practical use of unmodified MGF
- • Local injection site reactions
- • Theoretical cancer risk from sustained satellite cell proliferation
- • No human clinical trial safety data available
- • Potential for uncontrolled cell proliferation with chronic use
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| IGF-1 LR3 | Sequential/complementary | MGF for satellite cell activation, then IGF-1 LR3 for differentiation; don't combine simultaneously |
| PEG-MGF | Extended duration version | PEGylated form provides sustained activity; do not stack with unmodified MGF |
| Growth hormone | Synergistic | GH increases systemic IGF-1; MGF adds local repair signaling |
| NSAIDs | Potentially antagonistic | NSAIDs may blunt the inflammatory signals that trigger endogenous MGF expression |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
MGF is a anabolic compound with research interest in muscle repair, igf-1 variant, recovery. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying anabolic processes and muscle development
- • Individuals interested in muscle repair under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Goldspink G.. Gene expression in skeletal muscle. Biochem Soc Trans (2002). doi: 10.1042/bst0300285 PMID: 12023867
- [2] Yang SY, Goldspink G.. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett (2002). doi: 10.1016/S0014-5793(02)03918-0 PMID: 12445723
- [3] Carpenter V, Matthews K, Devlin G, et al.. Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction. Heart Lung Circ (2008). doi: 10.1016/j.hlc.2007.04.013 PMID: 18054270
- [4] Shyu KG, Ko WH, Yang WS, et al.. Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes. Cardiovasc Res (2005). doi: 10.1016/j.cardiores.2005.08.006 PMID: 16171793